Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Receivables - Net: 2014-2025

Historic Receivables - Net for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $1.6 million.

  • CytomX Therapeutics' Receivables - Net fell 51.40% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 51.40%. This contributed to the annual value of $3.1 million for FY2024, which is 9.59% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Receivables - Net of $1.6 million as of Q3 2025, which was down 12.84% from $1.9 million recorded in Q2 2025.
  • CytomX Therapeutics' Receivables - Net's 5-year high stood at $36.0 million during Q4 2022, with a 5-year trough of $756,000 in Q1 2021.
  • For the 3-year period, CytomX Therapeutics' Receivables - Net averaged around $3.3 million, with its median value being $2.4 million (2023).
  • Per our database at Business Quant, CytomX Therapeutics' Receivables - Net tumbled by 99.42% in 2021 and then spiked by 4,455.19% in 2022.
  • Over the past 5 years, CytomX Therapeutics' Receivables - Net (Quarterly) stood at $790,000 in 2021, then skyrocketed by 4,455.19% to $36.0 million in 2022, then crashed by 90.46% to $3.4 million in 2023, then fell by 9.59% to $3.1 million in 2024, then slumped by 51.40% to $1.6 million in 2025.
  • Its Receivables - Net was $1.6 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.0 million in Q1 2025.